Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 1L | First line |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| ASCO | American Society of Clinical Oncology |
| BID | Twice daily |
| CAS | Chemical Abstracts Service |
| cEGFR | Common EGFR mutations |
| CGP | Comprehensive genomic profiling |
| ChT | Chemotherapy |
| CI | Confidence interval |
| CLN-081 | Development code for Zipalertinib |
| CNS | Central nervous system |
| CR | Complete response |
| CYP | Cytochrome P450 |
| DCR | Disease control rate |
| DDI | Drug-drug interaction |
| DFS | Disease-free survival |
| DOR | Duration of response |
| ECOG PS | Eastern Cooperative Oncology Group performance status |
| EGFR | Epidermal growth factor receptor |
| EGFRex20ins | EGFR exon 20 insertions |
| ESMO | European Society for Medical Oncology |
| FDA | U.S. Food and Drug Administration |
| HR | Hazard ratio |
| IASLC | International Association for the Study of Lung Cancer |
| ICER | Incremental cost-effectiveness ratio |
| ICR | Independent central review |
| LMD | Leptomeningeal disease |
| mDOR | Median duration of response |
| MET | Mesenchymal-epithelial transition factor receptor |
| mPFS | Median progression-free survival |
| NDA | New Drug Application |
| NGS | Next-generation sequencing |
| NSCLC | Non-small-cell lung cancer |
| ORR | Objective response rate |
| OS | Overall survival |
| PCR | Polymerase chain reaction |
| PDUFA | Prescription Drug User Fee Act |
| PFS | Progression-free survival |
| PPPM | Per patient per month |
| QALY | Quality-adjusted life-year |
| RANO-BM | Response Assessment in Neuro-Oncology Brain Metastases |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RT | Radiotherapy |
| rwOS | Real-world overall survival |
| SDS | Safety data sheet |
| TAS6417 | Development code for Zipalertinib |
| TKI | Tyrosine kinase inhibitor |
| Tmax | Time to maximum plasma concentration |
| TRAE | Treatment-related adverse event |
| WCLC | World Conference on Lung Cancer |
| WT | Wild type |
| ≥2L | Second or later line |